Inside EU Health Inside EU Health: Cancer-causing chemicals; patient groups want HTA improvements; benefits of investing in innovative medicines EU agrees tougher protections against cancer-causing chemicals; patient groups welcome progress on EU HTA while calling for further improvements; every €1 invested in innovative medicines returns €5.67 in benefits, claims EFPIA
Inside EU Health Inside EU Health: Biotech Act(s); WHO preparedness; and study on drug spending dynamics Biotech Act(s); WHO preparedness; EMA consults on primates in research; and IQVIA study on drug spending dynamics
